The global islet amyloid polypeptide market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of metabolic disorders and gastrointestinal diseases, which are major drivers for the growth of this market.
The global islet amyloid polypeptide market by type includes A253, DACR042, DACR089, KB056 and KB088. The A253 segment accounted for the largest share in 2018 owing to its high therapeutic potential in treating various metabolic disorders such as diabetes mellitus type 2 (DM2). The DM2 segment accounted for the largest share in 2018 owing to its high prevalence rate globally.
The global islet amyloid polypeptide market by application includes metabolic disorders and gastrointestinal diseases. Metabolic disorders accounted for the largest share in 2018 due to their high prevalence rate globally and increasing incidence rates across different regions such as North America and Europe. Gastrointestinal diseases accounted for a significant share in 2018 due to their high incidence rates across different regions such as Asia Pacific and Middle East & Africa.
Some Of The Growth Factors Of This Market:
- The global population is aging and the incidence of diabetes is increasing.
- The number of people with type 2 diabetes is expected to increase by more than 50% in the next 20 years, which will lead to an increased demand for insulin and other treatments for diabetes.
- There are no known cures for type 1 or type 2 diabetes, so there will be a need for new treatments that can help manage blood sugar levels and prevent complications from developing in patients with these conditions.
- Islet amyloid polypeptide (IAPP) has been shown to play a role in the development of beta-cell dysfunction, which may lead to type 2 diabetes; therefore, IAPP could be a potential target for new therapies that could help prevent or delay the onset of this disease.
- IAPP has also been shown to play a role in Alzheimer's disease pathology; therefore, it may have therapeutic potential as well.
Industry Growth Insights published a new data on “Islet Amyloid Polypeptide Market”. The research report is titled “Islet Amyloid Polypeptide Market research by Types (AC-253, DACRA-042, DACRA-089, KBP-056, KBP-088, Others), By Applications (Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Others), By Players/Companies Adocia SAS, AstraZeneca Plc, Eli Lilly and Co, Neurimmune Holding AG, Nordic Bioscience A/S, Prothena Corp Plc, reMYND NV, Zealand Pharma AS”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Islet Amyloid Polypeptide Market Research Report
By Type
AC-253, DACRA-042, DACRA-089, KBP-056, KBP-088, Others
By Application
Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Others
By Companies
Adocia SAS, AstraZeneca Plc, Eli Lilly and Co, Neurimmune Holding AG, Nordic Bioscience A/S, Prothena Corp Plc, reMYND NV, Zealand Pharma AS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Islet Amyloid Polypeptide Market Report Segments:
The global Islet Amyloid Polypeptide market is segmented on the basis of:
Types
AC-253, DACRA-042, DACRA-089, KBP-056, KBP-088, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adocia SAS
- AstraZeneca Plc
- Eli Lilly and Co
- Neurimmune Holding AG
- Nordic Bioscience A/S
- Prothena Corp Plc
- reMYND NV
- Zealand Pharma AS
Highlights of The Islet Amyloid Polypeptide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AC-253
- DACRA-042
- DACRA-089
- KBP-056
- KBP-088
- Others
- By Application:
- Metabolic Disorders
- Gastrointestinal
- Musculoskeletal Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Islet Amyloid Polypeptide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Islet amyloid polypeptide (IAPP) is a protein that is found in the pancreas. It can cause problems with the pancreas, including pancreatitis and diabetes.
Some of the key players operating in the islet amyloid polypeptide market are Adocia SAS, AstraZeneca Plc, Eli Lilly and Co, Neurimmune Holding AG, Nordic Bioscience A/S, Prothena Corp Plc, reMYND NV, Zealand Pharma AS.
The islet amyloid polypeptide market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Islet Amyloid Polypeptide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Islet Amyloid Polypeptide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Islet Amyloid Polypeptide Market - Supply Chain
4.5. Global Islet Amyloid Polypeptide Market Forecast
4.5.1. Islet Amyloid Polypeptide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Islet Amyloid Polypeptide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Islet Amyloid Polypeptide Market Absolute $ Opportunity
5. Global Islet Amyloid Polypeptide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
5.3.1. AC-253
5.3.2. DACRA-042
5.3.3. DACRA-089
5.3.4. KBP-056
5.3.5. KBP-088
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Islet Amyloid Polypeptide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
6.3.1. Metabolic Disorders
6.3.2. Gastrointestinal
6.3.3. Musculoskeletal Disorders
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Islet Amyloid Polypeptide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Islet Amyloid Polypeptide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Islet Amyloid Polypeptide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Islet Amyloid Polypeptide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Islet Amyloid Polypeptide Demand Share Forecast, 2019-2026
9. North America Islet Amyloid Polypeptide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Islet Amyloid Polypeptide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
9.4.1. Metabolic Disorders
9.4.2. Gastrointestinal
9.4.3. Musculoskeletal Disorders
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
9.7.1. AC-253
9.7.2. DACRA-042
9.7.3. DACRA-089
9.7.4. KBP-056
9.7.5. KBP-088
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Islet Amyloid Polypeptide Demand Share Forecast, 2019-2026
10. Latin America Islet Amyloid Polypeptide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Islet Amyloid Polypeptide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
10.4.1. Metabolic Disorders
10.4.2. Gastrointestinal
10.4.3. Musculoskeletal Disorders
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
10.7.1. AC-253
10.7.2. DACRA-042
10.7.3. DACRA-089
10.7.4. KBP-056
10.7.5. KBP-088
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Islet Amyloid Polypeptide Demand Share Forecast, 2019-2026
11. Europe Islet Amyloid Polypeptide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Islet Amyloid Polypeptide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
11.4.1. Metabolic Disorders
11.4.2. Gastrointestinal
11.4.3. Musculoskeletal Disorders
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
11.7.1. AC-253
11.7.2. DACRA-042
11.7.3. DACRA-089
11.7.4. KBP-056
11.7.5. KBP-088
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Islet Amyloid Polypeptide Demand Share, 2019-2026
12. Asia Pacific Islet Amyloid Polypeptide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Islet Amyloid Polypeptide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
12.4.1. Metabolic Disorders
12.4.2. Gastrointestinal
12.4.3. Musculoskeletal Disorders
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
12.7.1. AC-253
12.7.2. DACRA-042
12.7.3. DACRA-089
12.7.4. KBP-056
12.7.5. KBP-088
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Islet Amyloid Polypeptide Demand Share, 2019-2026
13. Middle East & Africa Islet Amyloid Polypeptide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Islet Amyloid Polypeptide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Islet Amyloid Polypeptide Market Size and Volume Forecast by Application
13.4.1. Metabolic Disorders
13.4.2. Gastrointestinal
13.4.3. Musculoskeletal Disorders
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Islet Amyloid Polypeptide Market Size and Volume Forecast by Type
13.7.1. AC-253
13.7.2. DACRA-042
13.7.3. DACRA-089
13.7.4. KBP-056
13.7.5. KBP-088
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Islet Amyloid Polypeptide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Islet Amyloid Polypeptide Market: Market Share Analysis
14.2. Islet Amyloid Polypeptide Distributors and Customers
14.3. Islet Amyloid Polypeptide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Adocia SAS
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca Plc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly and Co
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Neurimmune Holding AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Nordic Bioscience A/S
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Prothena Corp Plc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. reMYND NV
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Zealand Pharma AS
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
